Clinical Scorecard: Organ Preservation for Rectal Adenocarcinoma: An Emerging Approach With Benefits and Challenges

At a Glance

Key Highlights

• US nonoperative management remained approximately 13% from 2006 to 2013, then increased to approximately 45% by 2023.
• Adoption accelerated after 2014 and increased more rapidly from 2019 to 2023; the article attributes this rise to broader intentional use of organ preservation.
• The NCDB analysis could not identify complete clinical response, treatment rationale, recurrence, salvage proctectomy, or long-term survival.
• Proctectomy is associated with sexual and urinary dysfunction, infertility, defecatory dysfunction after low anterior resection, and possible permanent ostomy after abdominoperineal resection.
• The article identifies concerns about excessive use, disparities in care, surveillance adherence, and effects on surgical trainee preparedness.

Guideline-Based Recommendations

Diagnosis

• The article describes organ preservation as an option following complete clinical response to neoadjuvant therapy; it does not provide diagnostic criteria for response.

Management

• Watch and wait is described as an alternative to proctectomy for selected patients with a complete clinical response.
• Trials establishing organ-preservation safety, particularly OPRA, used defined complete and near-complete clinical response criteria and specified intensive surveillance.

Monitoring & Follow-up

• Organ preservation requires complex surveillance, including frequent magnetic resonance imaging and endoscopies.
• The article calls for further research on surveillance adherence and oncologic outcomes as use expands.

Risks

• Routine-practice outcomes may not match trial results; an NCDB analysis of 2004–2014 found lower 5-year overall survival among nonoperatively managed patients with stage II and III disease than among matched controls.
• Potential concerns include excessive use, disparities in guideline-concordant care, and reduced surgical trainee preparedness.

Patient & Prescribing Data

Patients with stage II or III rectal adenocarcinoma considered for nonoperative management after neoadjuvant therapy; the article does not provide medication prescribing data.

Patients offered the respective risks and benefits of surgery versus organ preservation often elect watch and wait. The article reports no drug regimens or dosing.

Clinical Best Practices

• For organ preservation, use the rigorously defined response criteria and intensive surveillance approach described in the trials cited by the article.
• Discuss the potential functional consequences of proctectomy alongside the surveillance demands and uncertainties of watch and wait.
• Assess surveillance adherence and oncologic outcomes as organ-preservation use expands.
• Further research is needed to evaluate disparities in complete clinical response and long-term survival and to monitor effects on surgical training.

Related Resources & Content

• Keeling et al. National Cancer Database analysis of organ-preservation uptake, 2006–2023 (citation details not provided in source text).
• Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial (citation details not provided in source text).